Charged Alpha logo
CHARGED ALPHA
Stock Analysis
Home Shows Games YouTube
Tools
Stock Screener Stocks Mutual Funds Funds ETF Screener ETFs Crypto Screener Crypto Options Scanner Options Bond Dashboard Rates REIT Screener REITs Forex Heatmap FX Commodities Futures Earnings Calendar Reports Precious Metals Metals Stock Charts Charts
Stock Library / OGN
OGN Unclassified Latest YouTube: Q2 2026 Published 2026-08-01

OGN

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Organon (OGN): EPS Falls 15% — Is the $14 Sun Pharma Buyout Worth It?

Published 2026-08-01

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q2 2026
2026-08-01
Podcast available
Yes
Current price
$13.56
+0.01 (+0.07%)
Trailing / Forward P/E
17.38x
Forward: 3.73x
Market cap / Volume
—
Volume: —
Revenue / Earnings Growth
-2.3%
Earnings: -28.3%
Margins
20.7% op
Gross: 53.4% · Net: 3.4%
Balance sheet
1.95x current
Debt / Equity: 850.2
52-week range / Beta
$5.69 - $13.60
Beta: 1.52
Analyst target
$11.25
Upside: -17.0%
Cash / shareholder return
13.78% FCF yield
Dividend yield: 0.59%

Company context

Industry: Drug Manufacturers - General
Country: United States
Employees: —
Price to book: 3.94x
Return on equity: 24.0%
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Price chart

Market context for OGN

Competitive view

OGN vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

OGN latest YouTube video thumbnail YouTube
OGN
OGN
YouTube Podbean
Latest video
Q2 2026
Growth profile looks mature or currently muted, which can cap multiple expansion unless execution improves.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
SS&C Technologies Holdings Inc. latest YouTube video thumbnail YouTube
SS&C Technologies Holdings Inc.
SSNC
YouTube Podbean
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Danaher Corporation latest YouTube video thumbnail YouTube
Danaher Corporation
DHR
YouTube Podbean
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
OGN
$3.56B
OGN
SSNC
$18.63B
SS&C Technologies Holdings Inc.
DHR
$138.84B
Danaher Corporation
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
OGN
17.4x
OGN
SSNC
22.8x
SS&C Technologies Holdings Inc.
DHR
35.1x
Danaher Corporation
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
OGN
3.7x
OGN
SSNC
10.3x
SS&C Technologies Holdings Inc.
DHR
21.2x
Danaher Corporation
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
OGN
-2.3%
OGN
SSNC
10.3%
SS&C Technologies Holdings Inc.
DHR
5.5%
Danaher Corporation
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
OGN
-28.3%
OGN
SSNC
34.7%
SS&C Technologies Holdings Inc.
DHR
59.7%
Danaher Corporation
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
OGN
20.7%
OGN
SSNC
24.6%
SS&C Technologies Holdings Inc.
DHR
19.8%
Danaher Corporation
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
OGN
53.4%
OGN
SSNC
48.1%
SS&C Technologies Holdings Inc.
DHR
58.8%
Danaher Corporation
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
OGN
3.4%
OGN
SSNC
13.2%
SS&C Technologies Holdings Inc.
DHR
15.9%
Danaher Corporation
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
OGN
24.0%
OGN
SSNC
12.6%
SS&C Technologies Holdings Inc.
DHR
7.6%
Danaher Corporation
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
OGN
13.8%
OGN
SSNC
7.0%
SS&C Technologies Holdings Inc.
DHR
3.1%
Danaher Corporation
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
OGN
850.20x
OGN
SSNC
115.90x
SS&C Technologies Holdings Inc.
DHR
52.97x
Danaher Corporation
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
OGN
1.95x
OGN
SSNC
1.06x
SS&C Technologies Holdings Inc.
DHR
1.65x
Danaher Corporation
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
OGN
1.52
OGN
SSNC
1.09
SS&C Technologies Holdings Inc.
DHR
0.80
Danaher Corporation
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
OGN
0.6%
OGN
SSNC
0.7%
SS&C Technologies Holdings Inc.
DHR
0.7%
Danaher Corporation
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
OGN
-17.0%
OGN
SSNC
16.3%
SS&C Technologies Holdings Inc.
DHR
15.4%
Danaher Corporation

Related research

Non-quarter videos featuring OGN

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-31

Organon (OGN): EPS Down 15%, Stock Unchanged — Why? #shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for OGN

Each row is one earnings episode with every verified platform link available.

Q2 2026
Episode live
2026-08-01
Published youtube podcast complete
Organon (OGN): EPS Falls 15% — Is the $14 Sun Pharma Buyout Worth It?
Quarterly earnings-analysis entry for OGN. Use the links on the right to open the video or podcast episode.
YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music